Biosimilars Council commends Senate passage of Cornyn-Blumenthal Patent Thicket legislation

The Biosimilars Council applauded the recent unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-Texas) and Senator Blumenthal (D-Conn.) The bill is aimed at reforming patent abuse in the pharmaceutical industry.

[Read more: A new environment for biosimilars]

"The Biosimilars Council and AAM applauds unanimous Senate passage of the Cornyn-Blumenthal legislation," said Craig Burton, executive director of the Biosimilars Council. "Patent thickets are used by brand pharmaceutical companies to maintain high prices and deny patients access to lower-cost medicines. This legislation is a great step in curbing these abuses and will help increase competition and access for biosimilars. We encourage the House to take up this legislation and for Congress to continue working to help lower costs for patients."